{"url_path":"/sec/traw/8-k/2026-06-12/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-12","source_url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-073593-index.html","accession_number":"0001104659-26-073593","cik":"0001130598","ticker":"TRAW","issuer_name":"Traws Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1130598/0001104659-26-073593-index.html","primary_entity_key":"0001130598","primary_entity_name":"Traws Pharma, Inc."},"word_count":370,"has_tables":true,"body_markdown":"**Item 7.01 Regulation FD Disclosure.**\n\n \n\nOn June 12, 2026, Traws Pharma,\nInc. (the “Company”) issued a press release (the “Press Release”) announcing that the planned test of tivoxavir\nmarboxil in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom’s\nMedicines and Healthcare Products Regulatory Agency. A copy of the Press Release is attached as Exhibit 99.1 to this Current Report on\nForm 8-K (this “Current Report”) and is incorporated by reference into this Item 7.01.\n\n \n\nThe information included in this\nCurrent Report under this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for the purposes\nof Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities\nof that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities\nAct of 1933, as amended, except as expressly set forth by specific reference in such a filing.\n\n \n\n**Forward-Looking Statements**\n\n \n\nThis Current Report, including\nExhibit 99.1, contains certain forward-looking statements that involve substantial risks and uncertainties. When used herein, the terms\n“anticipates,” “expects,” “estimates,” “believes,” “will” and similar expressions,\nas they relate to the Company or its management, are intended to identify such forward-looking statements.\n\n \n\nForward-looking statements in\nthis Current Report, including Exhibit 99.1, or hereafter, including in other publicly available documents filed with the Securities and\nExchange Commission, reports to the stockholders of the Company and other publicly available statements issued or released by the Company\ninvolve known and unknown risks, uncertainties and other factors which could cause the Company’s actual results, performance (financial\nor operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied\nby such forward-looking statements. Such future results are based upon management’s reasonable estimates based upon current conditions\nand the most recent results of operations. These risks include, but are not limited to, the risks set forth herein and in such other documents\nfiled with the Securities and Exchange Commission, each of which could adversely affect the Company’s business and the accuracy\nof the forward-looking statements contained herein."}